Global Antisense & RNAi Therapeutics Market Report 2021-2025 & 2030 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma
News provided by
Share this article
Share this article
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational New Drug (IND) application for the company s lead candidate, STP705, for the treatment of skin squamous cell carcinoma
in situ (isSCC).
The research report presents a comprehensive assessment of the Primary Sclerosing Cholangitis Market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. Primary Sclerosing Cholangitis with 100+ market data Tables, Pie Chat, Graphs & Figures spread.
Oligonucleotide Therapeutics and Delivery 2021
SMi reports: Speakers confirmed at Oligonucleotide Therapeutics and Delivery Conference, which will convene in London on 22nd and 23rd September. LONDON, LONDON BRIDGE , UNITED KINGDOM, May 11, 2021 /EINPresswire.com/ Oligonucleotidetherapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. The Oligonucleotide Therapeutics and Delivery conference is here to keep you updated with discussions that will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions. This year’s agenda will encompass key drivers and hot topics of the industry including recent advances in oligonucleotide therapeutics, optimising oligonucleotide development strategies, clinical advances of RNAi therapy and emerging delivery solutions.